Periodic Reporting for period 2 - GenoMed4ALL (Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases)
Período documentado: 2022-07-01 hasta 2023-12-31
GenoMed4All is a European initiative to transform the response to haematological diseases by seizing the power of Artificial Intelligence (AI) and standardized interoperable sharing of cross-border data. For doing so, the project will support the pooling of genomic, clinical data and other “-omics” health data through a secure and privacy respectful data sharing platform based on the novel Federated Learning (FL) scheme, to advance research in personalised medicine.
GenoMed4All makes use of the existing infrastructures and initiatives, including powerful High-Performance Computing (HPC) facilities, hospital registries, data processing tools, and pre-existing repositories towards facilitating personalised medicine in common, rare and ultrarare haematological diseases to demonstrate the versatility and utility of the solutions. The strategy is defined to start to integrate the 10 clinical partners to later enlarge it to the overall 66 relevant clinical repositories in 15 Member States that ERN-EuroBloodNet members involve, besides 20 repositories not present in EuroBloodNet.
GenoMed4All aims to demonstrate the potential and benefits of trustable and explainable AI technologies, with a novel approach to AI models and algorithms (deep learning, variational autoencoders, generative models, besides combining with advanced statistical and Machine learning) to exploit the powerful set of “-omics” data which will be at researchers’ disposal leading to more reliable and meaningful outcomes for advancing research and personalised medicine, with 3 use cases covering oncological and non-oncological Haematological Diseases (HD). It will allow for identifying new knowledge, to support clinical research and decision making by linking Europe's relevant genomic repositories in haematological diseases, while ensuring full compliance with data protection legislation and ethical principles and increasing the AI trust for personalized medicine and impact.
GenoMed4All makes use of the existing infrastructures and initiatives, including powerful High-Performance Computing (HPC) facilities, hospital registries, data processing tools, and pre-existing repositories towards facilitating personalised medicine in common, rare and ultrarare haematological diseases to demonstrate the versatility and utility of the solutions. The strategy is defined to start to integrate the 10 clinical partners to later enlarge it to the overall 66 relevant clinical repositories in 15 Member States that ERN-EuroBloodNet members involve, besides 20 repositories not present in EuroBloodNet.
GenoMed4All aims to demonstrate the potential and benefits of trustable and explainable AI technologies, with a novel approach to AI models and algorithms (deep learning, variational autoencoders, generative models, besides combining with advanced statistical and Machine learning) to exploit the powerful set of “-omics” data which will be at researchers’ disposal leading to more reliable and meaningful outcomes for advancing research and personalised medicine, with 3 use cases covering oncological and non-oncological Haematological Diseases (HD). It will allow for identifying new knowledge, to support clinical research and decision making by linking Europe's relevant genomic repositories in haematological diseases, while ensuring full compliance with data protection legislation and ethical principles and increasing the AI trust for personalized medicine and impact.
GenoMed4All has achieved significant milestones. Key achievements include executing Joint Controller Agreements for data protection, developing a secure Federated Learning platform, and validating data pipelines for primary use cases. Additionally, the project has analyzed available data using advanced AI algorithms, developed clinical decision support systems, and initiated pilot evaluations to assess the clinical utility of its solutions. Deployment of components in local nodes in hospitals is in progress, demonstrating the versatility and utility of the solutions.
GenoMED4All progressed beyond the SoA in different areas: novel insights in haematological diseases thanks to the use of AI, federated learning provision adapted to this area needs, new preprocessing of multiomics information and improved HD pipelines.
In relation to maximising the visibility and potential impact of GenoMed4ALL outcomes, an aggregated set of more than 1K posts have been created in social media, 36 blog entries, 15 Zenodo publications (and 30 peer-reviewed publications in the pipeline). Moreover, a total of 25 events have been featured, 8 workshops hosted and 5 webinars have been attended. With regards to the online community, we have more than 1.6K followers in Twitter/X and Linkedin, and finally hardcopy promotional materials and campaign items have been updated during this period.
The enlargement of the community and federated has continued to be grown with specific coordinated engagement and onboarding activities. Cooperation with other initiatives to consolidate the network involved directly and indirectly with GenoMed4All has continued as well, focusing on ERN-EuroBloodNet, HARMONY, SYNTHEMA and Moffit actions. The GenoMed4ALL training programme has been created in collaboration with ERN-EUROBlodNet, and its first wave of webinars launched in September 2023.
11 Key Exploitable Results have been identified with the partners, and exploitation strategies are being discussed with the partners. These KERs include technological platform and services, as well as AI-based services for clinical support.
In relation to maximising the visibility and potential impact of GenoMed4ALL outcomes, an aggregated set of more than 1K posts have been created in social media, 36 blog entries, 15 Zenodo publications (and 30 peer-reviewed publications in the pipeline). Moreover, a total of 25 events have been featured, 8 workshops hosted and 5 webinars have been attended. With regards to the online community, we have more than 1.6K followers in Twitter/X and Linkedin, and finally hardcopy promotional materials and campaign items have been updated during this period.
The enlargement of the community and federated has continued to be grown with specific coordinated engagement and onboarding activities. Cooperation with other initiatives to consolidate the network involved directly and indirectly with GenoMed4All has continued as well, focusing on ERN-EuroBloodNet, HARMONY, SYNTHEMA and Moffit actions. The GenoMed4ALL training programme has been created in collaboration with ERN-EUROBlodNet, and its first wave of webinars launched in September 2023.
11 Key Exploitable Results have been identified with the partners, and exploitation strategies are being discussed with the partners. These KERs include technological platform and services, as well as AI-based services for clinical support.